John Johnson, OD
Optometrist · Hilton Head Island, SCNPI 1992881239
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,090 of the $6,417 with a category attached, or 79.3%. 24 manufacturers reported payments, led by Biotissue Holdings Inc. at 32.0% of the total. Reporting peaked in 2022 at $2,170 and has fallen 61.9% since, to $827 in 2025. Among optometrist clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $36.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- Sun Pharmaceutical Industries Inc.$1K
- AbbVie$433
- Bausch & Lomb, A Division Of Bausch Health US, LLC$301
- Kala Pharmaceuticals, Inc.$287
- Alcon$286
- plus $2K from 18 others
What the payments were for
- Travel & lodging$1,21219%
- Food & beverage$5,09079%
- Gifts$190%
- Entertainment$951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 11 | $2,054 |
| Sun Pharmaceutical Industries Inc. | 83 | $1,374 |
| AbbVie(2 entities) | 12 | $433 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $301 |
| Kala Pharmaceuticals, Inc. | 3 | $287 |
| Alcon | 10 | $286 |
| Shire North American Group Inc | 4 | $277 |
| Aerie Pharmaceuticals, Inc. | 7 | $179 |
| Mallinckrodt Hospital Products Inc. | 4 | $173 |
| Tarsus Pharmaceuticals, Inc. | 5 | $155 |
| Oyster Point Pharma, Inc. | 1 | $136 |
| Optos, Inc. | 4 | $112 |
| Amgen | 1 | $110 |
| Novartis | 5 | $94 |
| Rxsight Inc | 1 | $93 |
| Bausch & Lomb Americas Inc. | 4 | $78 |
| Coopervision Inc. | 1 | $78 |
| Taro Pharmaceuticals USA, Inc. | 1 | $42 |
| Maculogix, Inc. | 1 | $39 |
| Eyevance Pharmaceuticals LLC | 2 | $35 |
| Dompe US, Inc. | 1 | $29 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Omeros Corporation | 1 | $19 |
| Thea Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$1,565
- AmnioGraft$1,565
- CEQUA$587
- INVELTYS$266
- XIIDRA$241
- TYRVAYA$136
- DURYSTA$125
- AmnioGuard$111
- TEPEZZA$110
How this compares
$6,417 in reported general payments places this provider in the 90th percentile of 653 optometrist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 64 | $74,545 |
| LumiganBimatoprost | 96 | $62,494 |
| XiidraLifitegrast | 17 | $27,272 |
| MieboPerfluorohexyloctane/Pf | 19 | $25,120 |
| Lotemax SmLoteprednol Etabonate | 42 | $11,033 |
| Cyclosporine | 21 | $10,466 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $8,546 |
| CequaCyclosporine | 11 | $8,283 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 210 | $7,919 |
| Loteprednol Etabonate | 34 | $6,584 |
| Fluorometholone | 65 | $4,968 |
| Doxycycline Hyclate | 150 | $4,386 |
| VyzultaLatanoprostene Bunod | 14 | $4,256 |
| RocklatanNetarsudil Mesylat/Latanoprost | 12 | $3,944 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $3,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $433 | $145,585179 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $78 | $56,64950 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $301 | $17,61776 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,374 | $8,28311 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $179 | $3,94412 claims |
| AlconSimbrinza | $286 | $3,26314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 optometrist providers in South Carolina.
Other optometrist in Hilton Head Island
- Michael CampbellHilton Head Island$6K
- Thomas WeshefskyMyrtle Beach$77K
- Richard BedellCharleston$55K
- Patrick VollmerColumbia$49K
- William ColemanEasley$22K
- Furman SmithMt Pleasant$21K
- Jennifer ZolmanCharleston$21K
- Steven AndreasenGreenville$19K
- Bridget WhaleyGreenville$18K
- Scott OliverRock Hill$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.